Making the pharma industry future-proof through supply chain digitalization

Supply chain digitalization, or rather digital transformation, provides a path to sustainable solutions for many of the challenges in managing the pharmaceutical industry’s supply chain such as compliance, traceability, end-to-end visibility, error-reduction, quality assurance and process efficiencies.
Supply chain digitalization also prepares pharma companies for a future where the impact of disruptive technologies and events will likely bring new problems and opportunities

Pharma supply chain digitalization

For instance, the covid-19 pandemic, which has challenged the pharma industry by disrupting supply chains while also creating opportunities for industry players to participate in vaccine clinical trials, is a typical example of this dynamic at work. In addition, according to the KPMG Pharma Outlook 2030 report, the coming years will see the balance of power between pharma companies and governments shift further in favour of governments and insurers who are keen to keep drug prices low, putting more pressure on pharma companies to re-strategize for sustainability.  

In view of these and other factors, supply chain digitalization is likely to remain relevant beyond 2020. Key to its success, however, is the implementation of efficient integrations to facilitate the free flow of data and enable the discovery of significant insights that can be applied to improving pharma company operations.

Emerging technologies and benefits

Whether by outsourcing or by enhancing in-house capabilities, implementing the digital transformation of the supply chains is one way for pharmaceutical companies to future–proof their operations. It positions industry players to tackle the long-standing challenges outlined above by leveraging Artificial Intelligence, Big Data, Predictive Analytics and Cloud computing, all of which can lead to significant efficiencies and competitive advantages. That said, it takes efficient data integration to realise the benefits of digitalization effectively and sustainably.

Getting integrations right

End-to-end supply chain visibility, the holy grail of supply chain management, is impossible to achieve without digitalization and capturing data from several source.  

To overcome the inefficiencies of point-to-point connections, TSS has adopted a technology-agnostic platform. As the CPO at TSS, Tobias Holmer, puts it,

“At TSS, our use of a third-party gateway allows us to support both old and new integration technologies at any scale. It’s a flexible solution, letting us integrate virtually any system into a larger whole.”  

The benefits of getting integration right

A technology-agnostic model of integrations allows for the free flow of data from multiple sources in real-time. It is therefore the best enabler of the benefits of supply chain digitalization including cost reduction, GxP data compliance, precision in supply chain management, end-to-end visibility and most importantly, faster product releases.

Efficient release process - a key benefit

Speeding up the release process is key to the sustainability of pharma companies. It means efficient product development cycles supported by clinical trials where the occurrence of excursions and excursion-related downtimes are minimized. It also means ensuring that pharma products are delivered in a safe and timely manner.

Supply chain digitalization sets in motion a virtuous cycle that will keep pharma companies future-ready and help the industry rise to the challenges of providing medicines in the 21st century. However, it is a process of many parts and getting integration right is a vital component of making digital transformation a success.

To find out more about the technology-agnostic solutions for temperature management provided by TSS, request a consultation today.

You may also be interested in

Data-driven supply chains: improving your excursion rate and temperature performance in 5 steps

Data is an essential requirement for improving supply chain processes. But that doesn’t mean that simply collecting more of it will instantly lead to reductions in waste, increases in efficiency and lower excursion rates. Taking a more targeted approach will help you turn supply chain data into insights that can help you understand exactly what is happening at every stage of your pharmaceutical supply chain.
Read moreDownload Whitepaper
Freezer for temperature monitoring.

Achieving FDA and EMA Compliance in Temperature Monitoring

Many pharmaceuticals and biological products require specific temperature conditions during manufacturing, storage, and transport to ensure their quality and safety. Failure to maintain these conditions can lead to product degradation, making them less effective or even dangerous.
Read moreDownload Whitepaper

We’re attending LogiPharma 2022

We’re pleased to announce that we’re attending LogiPharma 2022, the world’s leading Pharma Supply event, from April 05th to April 07th, in Nice, France.
Read moreDownload Whitepaper

You may also be interested in

Can You Rely on the Results from Your Clinical Trials?

The success of a clinical trial depends on the reliability of its data. Many investigational drugs are sensitive to temperature, and any temperature deviation can affect their quality and, in the worst case, patient safety. Automated and integrated temperature monitoring solutions help secure data quality, support compliance, and speed up the delivery of new medicines to patients.
Read more

Extending TempMonitor BLE to Ultra-Low Temperatures

Introducing the new TSS Dry Ice Probes, enginereed for accurate and GxP-compliant temperature monitoring down to –90°C. Available in two lengths for flexible setup — built to safeguard product integrity in every environment.
Read more

Subscribe to our newsletter

Sign up for our newsletter to receive all the latest TSS news and insights in temperature management solutions.